UroToday
VerifiedOnline/Digital
UroToday publishes evidence-based clinical content that is organized across the site by disease, treatments and guidelines. This educational platform offers written articles, video lectures or discussions and emerging data presented at conferences. The content across the site is developed, organized and presented by leaders across the urology field. Further, UroToday offers a portal providing access to enrolling clinical trials. The Centers of Excellence (CoE) provide state of the art lectures, original articles and research organized by disease and condition and focused on what is known about treatments or what is emerging in clinical care. Each CoE is led by a clinician-editor and invited faculty. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesPanitumumab plus Nab-Paclitaxel in Renal Medullary Carcinoma and a Prospective Registry - Pavlos Msaouel
Tian Zhang: Hi, and welcome to this episode of UroToday. I'm Tian Zhang, a GU medical oncologist at UT Southwestern in Dallas, Texas. I'm so pleased to be joined by my friend and colleague just south of us, Dr. Pavlos Msaouel, who is an associate professor in the Department of GU Medical Oncology at MD Anderson Cancer Center in Houston. Thanks so much for joining us here in Chicago. Pavlos Msaouel: Always a pleasure talking to you, Dr. Zhang.
ENLIGHTED Trial Update with VTP for Low-Grade Upper Tract Urothelial Cancer - Vitaly Margulis
Zachary Klaassen: Hi, my name is Zach Klaassen, urologic oncologist at the Georgia Cancer Center in Augusta Georgia. And I'm delighted to be joined with Dr. Vitaly Margulis, who is a urologic oncologist at UT Southwestern in Dallas. We're at ASCO 2026 in Chicago and we'll be discussing the ENLIGHTED trial, updates from this trial presented by Dr. Margulis this week. Vitaly, thanks so much for joining us as always on UroToday. Vitaly Margulis: Good to be with you, Zach.
The Predictive Role of [177Lu]Lu-PSMA-617 SPECT/CT Semiquantitative Parameters from the 1st RLT Cycle in Advanced mCRPC: A Preliminary Bicentric Lesion-Based Analysis - Beyond the Abstract
[¹⁷⁷Lu]Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is an effective option for advanced metastatic castration-resistant prostate cancer (mCRPC).1 Thanks to the [177Lu]Lu-characteristics (~10% of γ-emission), it is possible to image the biodistribution of the RLT with single-photon emission computed tomography/computed tomography (SPECT/CT) starting from 4 hours after the injection at each RLT cycle.2 The clinical role of post-RLT biodistribution imaging has been...
Pathological Assessment of Morcellated Tissue after ERBT: Insights from a Two-Round Delphi Survey - Beyond the Abstract
En bloc resection of bladder tumor (ERBT) is becoming increasingly popular because of several potential advantages over conventional trans urethral resection of bladder tumor (TURBT).
The Evolving PI-RADS Paradigm - Beyond the Abstract
While PI-RADS v2.1 has successfully established multiparametric MRI (mpMRI) as the international standard for prostate cancer diagnosis, everyday clinical practice continues to highlight areas where the framework can be further refined to improve consistency, reproducibility, and patient-centered care. Protocol Selection and Optimization A central issue in current practice is the choice of imaging protocol, particularly the role of biparametric MRI (bpMRI).
Cannabis use and testicular germ cell tumour subtypes in the french nationwide TESTIS case-control study.
Testicular germ cell tumours (TGCTs) are the most common malignancy among young men, and their rapidly increasing incidence suggests a role for modifiable risk factors. The role of increasingly prevalent cannabis use, particularly during developmental periods before biological maturation, in TGCT etiology remains unclear.
Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes.
To develop contemporary evidence-informed recommendations for robot-assisted radical cystectomy (RARC), urinary reconstruction, and perioperative management, integrating current evidence with the experience of Latin American experts in uro-oncology and robotic surgery. A modified Delphi consensus process was conducted involving 42 experts with extensive experience in RARC.
The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study.
Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30-40% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients with mRCC. However, the role of cytoreductive nephrectomy (CN) in the IO-TKI era, particularly for rare and understudied histologies such as non-clear-cell RCC, remains poorly understood.
MicroRNAs in Penile Cancer: A Systematic Review of Diagnostic, Prognostic, and Mechanistic Evidence.
Penile squamous cell carcinoma (PSCC) is a rare malignancy associated with substantial morbidity and limited prognostic biomarkers. MicroRNAs have been reported as candidate molecular markers and putative regulators of tumor biology in individual PSCC studies, but their clinical relevance remains uncertain. This systematic review aimed to map and summarize current evidence on candidate miRNAs in PSCC, with emphasis on reported diagnostic, prognostic, and mechanistic associations.
A Novel 7 Sialylation-Related LncRNA Signature as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.
Clear cell renal cell carcinoma (ccRCC) is the most common, aggressive renal malignancy with a poor prognosis and limited advanced therapies.Accumulating evidence highlights the importance of sialylation and sialylation-related long non-coding RNAs (lncRNAs) in tumor progression, immune evasion, and treatment resistance.